"Tumor Identity Cards (CIT)®" Database FRESH-PEF8214-en Fabien PETEL "Tumor Identity Cards (CIT)®" Database Annotator® FRESH-PEF8214-en 8214 FRESH-PEF8214 Mira AYADI Aurélien DE REYNIES Fabien PETEL LIGUE NATIONALE CONTRE LE CANCER (LNCC) Epidemiology France Portal (PEF) LIGUE NATIONALE CONTRE LE CANCER (LNCC) null Mira;AYADI Fabien;PETEL genome methylation patterns French National League Against Cancer alterations chromosomal rearrangement gene expression microRNA cancer cells personalised medicine exons Oncology Clinical immunology Neoplasms Behavioral determinants: Addiction Biological determinants: Genetic predisposition Environmental determinants: Other Behavioral determinants Healthcare system determinants: Use of care Socio-demographic and economic determinants: Employment Biological determinants Environmental determinants Healthcare system determinants Socio-demographic and economic determinants To comprehensively characterise and integrate cellular signals and associate them with patient history and treatments. Biological events can be genome alterations, mutations, chromosomal rearrangements, gene and miRNA expressions, methylation patterns, exon variations, etc.. As such, CIT is developing an integrated view of how cancer cells develop and function. This work forms the basis of personalised medicine that is adapted to the genomic characteristics of each tumour. CIT may then identify molecular signatures of patients who are more likely to respond well to a treatment, or whose cancer is deemed more aggressive, therefore helping MDs to choose the best treatment and care. null France Individuals Patients population Male Female Infant, Newborn (birth to 28 days) Infant (28 days to 2 years) Child, Preschool (2 to 5 years) Child (6 to 12 years) Young Adult (19 to 24 years) Adult (25 to 44 years) Middle Aged (45 to 64 years) Aged (65 to 79 years) Aged, 80 and over (80 years and more) Inclusion criteria depends on each cancer-specific project inside the CIT Programme, and relate to the biological and clinical questions raised by the PIs. Studies may involve patient monitoring within a hospital setting, or patients previously included in a prospective clinical study. Informed patient consent is obtained beforehand. Studied diseases may be paediatric tumours or adult cancers, and may apply to solid tumours or hematologic malignancies or lymphoma. Secure data access is restricted to the researchers involved in the Programme. Clinical data Biological data ICD external ontologies and internal semi-structured vocabulary Health event/morbidity Health event/mortality Others Other Through organizations (health services or institutions schools businesses etc.) [10000-20000[ individuals Converting or copying information into a structured record Interview with the participant (including clinical) Observational Study Observational Study Mid-2015, the CIT programme's database was containing histological, clinical and biological information from 13,000 anonymized patients, all types of cancer included, and 19,000 'omics' experiments (SNP/Expression/miRNA/Exon/Methylation; microarray or NGS). Unknown Restricted access Secure data access is restricted to the researchers involved in the CIT Programme Access on specific project only